ALLO - ASH Highlights a Series of Pre-Clinical Successes by Allogene

Two pre-clinical successes by Allogene Therapeutics (NASDAQ:ALLO) as announced at the ongoing Annual Meeting of the American Society of Hematology has failed to pique investor interest with share down ~11% on above average volume.The company headquartered in South San Francisco pioneers the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies against cancer.In models of acute myeloid leukemia, ALLO-316, an AlloCAR T™ therapy targeting CD70, has shown the ability to selectively kill CD70-expressing leukemic cells. CD70 is expressed in malignancies ranging from solid tumors such as RCC (Renal Cell Carcinoma), lung cancer, and glioblastoma to hematologic cancers, including AML.“These preclinical results in AML, coupled with previous findings of ALLO-316 in RCC presented at the American Association for Cancer Research Annual Meeting in 2019, reinforce our belief that CD70 may become one of the more important targets across a broad spectrum of cancers,” said Rafael Amado, M.D., Executive Vice

For further details see:

ASH Highlights a Series of Pre-Clinical Successes by Allogene